Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SERPINE1 | P05121 | 10/20 | 0.76 |
| ▸ | ICMT | O60725 | 8/20 | 0.47 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4030133 | 0.91 | SERPINE1 (0.70) | SERPINE1ICMTMAPK1L3MBTL1 | |
| SCHEMBL4936670 | 0.86 | SERPINE1 (1.00) | SERPINE1ICMTPLA2G2AMAPK1 | |
| Tiplasinin SCHEMBL29448190 | 0.79 | SERPINE1 (1.00) | SERPINE1ICMTPLA2G2AMAPK1L3MBTL1 | |
| Tiplasinin SCHEMBL3052065 | 0.79 | SERPINE1 (1.00) | SERPINE1ICMTPLA2G2AMAPK1L3MBTL1 | |
| SCHEMBL3865483 | 0.76 | SERPINE1 (0.79) | SERPINE1ICMTPLA2G2AMAPK1L3MBTL1 | |
| SCHEMBL24855093 | 0.76 | SERPINE1 (0.72) | SERPINE1PLA2G2AMAPK1L3MBTL1 | |
| SCHEMBL30844603 | 0.76 | SERPINE1 (0.72) | SERPINE1PLA2G2AMAPK1L3MBTL1 | |
| SCHEMBL3858555 | 0.76 | SERPINE1 (0.78) | SERPINE1ICMTPLA2G2A | |
| SCHEMBL3868588 | 0.74 | SERPINE1 (0.69) | SERPINE1ICMT | |
| SCHEMBL4750090 | 0.73 | SERPINE1 (0.83) | SERPINE1ICMT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1569902-B1 | SUBSTITUTED INDOLE OXO-ACETYL AMINO ACETIC ACID DERIVATIVES AS INHIBITORS OF PLASMINOGEN ACTIVATOR INHIBITOR-1 (PAI-1) | WYETH CORP (US) | 2009-05-06 | — | — | EP | claimed |
| EP-2010171-A2 | INHIBITORS OF PAI-1 FOR TREATMENT OF MUSCULAR CONDITIONS | Wyeth a Corporation of the State of Delaware (US) | 2009-01-07 | — | — | EP | claimed |
| WO-2007098278-A2 | INHIBITORS OF PAI-1 FOR TREATMENT OF MUSCULAR CONDITIONS | WYETH (US) | 2007-08-30 | — | — | WO | claimed |
| US-20070203220-A1 | Inhibitors Of PAI-1 For Treatment Of Muscular Conditions | WYETH (US) | 2007-08-30 | — | — | US | claimed |
| US-7160918-B2 | Substituted indole oxo-acetyl amino acetic acid derivatives as inhibitors of plasminogen activator inhibitor (PAI-1) | ELOKDAH HASSAN MAHMOUD | 2007-01-09 | — | — | US | claimed |
| US-7056943-B2 | Substituted indole oxo-acetyl amino acetic acid derivatives as inhibitors of plasminogen activator inhibitor-1 (PAI-1) | WYETH (US) | 2006-06-06 | — | — | US | claimed |
| EP-1569902-A1 | SUBSTITUTED INDOLE OXO-ACETYL AMINO ACETIC ACID DERIVATIVES AS INHIBITORS OF PLASMINOGEN ACTIVATOR INHIBITOR-1 (PAI-1) | Wyeth (US) | 2005-09-07 | — | — | EP | claimed |
| WO-2004052856-A1 | SUBSTITUTED INDOLE OXO-ACETYL AMINO ACETIC ACID DERIVATIVES AS INHIBITORS OF PLASMINOGEN ACTIVATOR INHIBITOR-1 (PAI-1) | WYETH (US) | 2004-06-24 | — | — | WO | claimed |
| US-20040116504-A1 | Substituted indole oxo-acetyl amino acetic acid derivatives as inhibitors of plasminogen activator inhibitor-1 (PAI-1) | WYETH | 2004-06-17 | — | — | US | claimed |
| EP-1569902-B1 | SUBSTITUTED INDOLE OXO-ACETYL AMINO ACETIC ACID DERIVATIVES AS INHIBITORS OF PLASMINOGEN ACTIVATOR INHIBITOR-1 (PAI-1) | WYETH CORP (US) | 2009-05-06 | — | — | EP | disclosed |
| EP-2010171-A2 | INHIBITORS OF PAI-1 FOR TREATMENT OF MUSCULAR CONDITIONS | Wyeth a Corporation of the State of Delaware (US) | 2009-01-07 | — | — | EP | disclosed |
| WO-2007098278-A2 | INHIBITORS OF PAI-1 FOR TREATMENT OF MUSCULAR CONDITIONS | WYETH (US) | 2007-08-30 | — | — | WO | disclosed |
| US-20070203220-A1 | Inhibitors Of PAI-1 For Treatment Of Muscular Conditions | WYETH (US) | 2007-08-30 | — | — | US | disclosed |
| US-7160918-B2 | Substituted indole oxo-acetyl amino acetic acid derivatives as inhibitors of plasminogen activator inhibitor (PAI-1) | ELOKDAH HASSAN MAHMOUD | 2007-01-09 | — | — | US | disclosed |
| US-20060122254-A1 | Substituted indole oxo-acetyl amino acetic acid derivatives as inhibitors of plasminogen activator inhibitor (PAI-1) | WYETH (US) | 2006-06-08 | — | — | US | disclosed |
| US-7056943-B2 | Substituted indole oxo-acetyl amino acetic acid derivatives as inhibitors of plasminogen activator inhibitor-1 (PAI-1) | WYETH (US) | 2006-06-06 | — | — | US | disclosed |
| EP-1569902-A1 | SUBSTITUTED INDOLE OXO-ACETYL AMINO ACETIC ACID DERIVATIVES AS INHIBITORS OF PLASMINOGEN ACTIVATOR INHIBITOR-1 (PAI-1) | Wyeth (US) | 2005-09-07 | — | — | EP | disclosed |
| WO-2004052856-A1 | SUBSTITUTED INDOLE OXO-ACETYL AMINO ACETIC ACID DERIVATIVES AS INHIBITORS OF PLASMINOGEN ACTIVATOR INHIBITOR-1 (PAI-1) | WYETH (US) | 2004-06-24 | — | — | WO | disclosed |
| US-20040116504-A1 | Substituted indole oxo-acetyl amino acetic acid derivatives as inhibitors of plasminogen activator inhibitor-1 (PAI-1) | WYETH | 2004-06-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070203220-A1 | Inhibitors Of PAI-1 For Treatment Of Muscular Conditions | SERPINE1, SERPINB1, SERPINC1 | SERPINE1 1/4885ICMT 4550/4885PLA2G2A 1905/4885 |
| US-20060122254-A1 | Substituted indole oxo-acetyl amino acetic acid derivatives as inhibitors of plasminogen activator inhibitor (PAI-1) | SERPINE1, F2RL1, F2R | SERPINE1 1/4885ICMT 2605/4885PLA2G2A 1306/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.